SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government
8 references·0 citing·21 second hop
Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government (2023)Drug Repurposing of Generic Drugs: Challe…Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers (2021)Drug repurposing: Misconcepti…Waste in covid-19 research (2020)Waste in covid-19 researchOn-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients (2020)On-Label or Off-Label? Overco…Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT) (2020)Cost-effectiveness of low-dos…Overcoming the legal and regulatory barriers to drug repurposing (2018)Overcoming the legal and regu…Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets (2018)Barriers for Access to New Me…How Much Longer Will We Put Up With $100,000 Cancer Drugs? (2017)How Much Longer Will We Put U…Creating New Economic Incentives for Repurposing Generic Drugs for Unsolved Diseases Using Social Finance (2015)Creating New Economic Incenti…Risks in new drug development: Approval success rates for investigational drugs (2001)Pricing in the Market for Anticancer Drugs (2015)The $2.6 Billion Pill — Methodologic and Policy Considerations (2015)Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies (2019)Specialty Drug Pricing and Out-of-Pocket Spending on Orally Administered Anticancer Drugs in Medicare Part D, 2010 to 2019 (2019)Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications (2021)Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis (2008)Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force (2013)American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options (2015)Medicine Shortages: Gaps Between Countries and Global Perspectives (2019)Fixed dose drug combinations – are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries (2020)Rapid Assessment of Price Instability and Paucity of Medicines and Protection for COVID-19 Across Asia: Findings and Public Health Implications for the Future (2020)Challenges and opportunities of drug repositioning (2013)Drug repurposing in oncology—patient and health systems opportunities (2015)Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics (2017)Avoidable waste in the production and reporting of research evidence (2009)The mental health impact of the covid-19 pandemic on healthcare workers, and interventions to help them: A rapid systematic review (2020)Implicit bias in healthcare: clinical practice, research and decision making (2021)Comparison of mental health symptoms before and during the covid-19 pandemic: evidence from a systematic review and meta-analysis of 134 cohorts (2023)Against pandemic research exceptionalism (2020)Drug repurposing in rare diseases: Myths and reality (2020)
this work references cited by second hop

References

  • 2020Waste in covid-19 research330 cited
  • 2018Overcoming the legal and regulatory barriers to drug repurposing227 cited
  • 2018Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets159 cited
  • 2021Drug repurposing: Misconceptions, challenges, and opportunities for academic researchers156 cited
  • 2017How Much Longer Will We Put Up With $100,000 Cancer Drugs?104 cited
  • 2020Cost-effectiveness of low-dose colchicine after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)88 cited
  • 2020On-Label or Off-Label? Overcoming Regulatory and Financial Barriers to Bring Repurposed Medicines to Cancer Patients79 cited
  • 2015Creating New Economic Incentives for Repurposing Generic Drugs for Unsolved Diseases Using Social Finance26 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work